Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat Rev Clin Oncol, vol.12, pp.408-424, 2015. ,
Guide for diagnosis and treatment of hepatocellular carcinoma, World J Hepatol, vol.7, issue.12, pp.1632-1651, 2015. ,
Regorafenib for treatment of hepatocellular carcinoma, Hepatology, vol.67, issue.3, pp.1162-1165, 2018. ,
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy, Oncotarget, vol.8, issue.33, pp.55715-55730, 2017. ,
Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma, World J Gastroenterol, vol.21, issue.42, pp.12022-12041, 2015. ,
Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers, Chem Sci, vol.8, issue.5, pp.3427-3433, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02174996
MicroRNAs in liver disease, Gastroenterology, vol.142, issue.7, pp.1431-1443, 2012. ,
Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding, Cell, vol.153, issue.3, pp.654-665, 2013. ,
MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling, Hepatol Commun, vol.1, issue.2, pp.168-183, 2017. ,
New tumor suppressor mi-croRNAs target glypican-3 in human liver cancer, Oncotarget, vol.8, issue.25, pp.41211-41226, 2017. ,
MicroRNAs in cancer: biomarkers, functions and therapy, Trends Mol Med, vol.20, issue.8, pp.460-469, 2014. ,
Therapeutic targeting of microRNAs: current status and future challenges, Nat Rev Drug Discovery, vol.13, issue.8, pp.622-638, 2014. ,
siRNA versus miRNA as therapeutics for gene silencing, Mol Ther Nucleic Acids, vol.4, p.252, 2015. ,
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis, Nat Commun, vol.7, p.13781, 2016. ,
Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein, Oncogene, vol.20, issue.20, pp.2606-2610, 2001. ,
Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5, Hepatology, vol.46, issue.6, pp.2003-2013, 2007. ,
Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma, Oncol Lett, vol.13, issue.3, pp.1041-1047, 2017. ,
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection, J Hepatol, vol.48, issue.1, pp.83-90, 2008. ,
Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method, Mol Cell Proteomics, vol.8, issue.8, pp.1777-1788, 2009. ,
A functional screening identifies five micrornas controlling glypican-3: role of mir-1271 down-regulation in hepatocellular carcinoma, Hepatology, vol.57, issue.1, pp.195-204, 2013. ,
Argininosuccinate synthase 1 (ASS1): a marker of unclassified hepatocellular adenoma and high bleeding risk, Hepatology, vol.66, issue.6, pp.2016-2028, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01550711
Semi-supervised learning for peptide identification from shotgun proteomics datasets, Nat Methods, vol.4, issue.11, pp.923-925, 2007. ,
The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition, Nucleic Acids Res, vol.45, issue.D1, pp.1100-1106, 2017. ,
Predicting effective mi-croRNA target sites in mammalian mRNAs, Elife, vol.4, p.5005, 2015. ,
0: a comprehensive atlas of mi-croRNA-target interactions, Nat Methods, vol.12, issue.8, pp.697-697, 2015. ,
Over-expression of c-raf-1 protooncogene in liver cirrhosis and hepatocellular carcinoma, Hepatol Res, vol.29, issue.2, pp.113-121, 2004. ,
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, vol.45, issue.1, pp.42-52, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00130313
Tracking cellular and molecular changes in a species-specific manner during experimental tumor progression in vivo, Oncotarget, vol.9, issue.22, pp.16149-16162, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01724071
Identification and bioinformatics analysis of miRNAs associated with human muscle invasive bladder cancer, Mol Med Rep, vol.16, issue.6, pp.8709-8720, 2017. ,
A tissue microRNA signature that predicts the prognosis of breast cancer in young women, PLoS ONE, vol.12, issue.11, p.187638, 2017. ,
Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma, PLoS ONE, vol.10, issue.3, p.120024, 2015. ,
Domainspecific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity, Proc Natl Acad Sci, vol.110, issue.3, pp.978-983, 2013. ,
Protein kinases that phosphorylate splicing factors: roles in cancer development, progression and possible therapeutic options, Int J Biochem Cell Biol, vol.91, pp.102-115, 2017. ,
Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis, Cancer Res, vol.75, issue.4, pp.754-765, 2015. ,
SMARCD1 regulates senescenceassociated lipid accumulation in hepatocytes, NPJ Aging Mech Dis, vol.3, p.11, 2017. ,
New insights into diagnosis and therapeutic options for proliferative hepatoblastoma, Hepatology, vol.68, issue.1, pp.89-102, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01677306
MEK-1 activates C-Raf through a Ras-independent mechanism, Biochim Biophys Acta, vol.1833, issue.5, pp.976-986, 2013. ,
New perspectives for targeting RAF kinase in human cancer, Nat Rev Cancer, vol.17, issue.11, pp.676-691, 2017. ,
miR-195 is a key regulator of Raf1 in thyroid cancer, Onco Targets Ther, vol.8, pp.3021-3028, 2015. ,
MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1, Tumour Biol, vol.35, issue.10, pp.10177-10184, 2014. ,
Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma, Eur J Surg Oncol, vol.37, issue.6, pp.513-520, 2011. ,
miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation, Liver Int, vol.00, pp.1-12, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02437915